人参皂苷Rg3胶囊联合化疗治疗中晚期非小细胞肺癌的疗效观察

摘要

Objective To observe the effect of ginsenoside Rg3 ( Shenyi capsule )on serum level of VEGF and treatment efficacy on NSCLC patients.Methods NSCLC patients who were in Ⅲ B and could not conduct operations were selected.In experiment group, patients have been treated by chemotherapy combined with ginsenoside Rg3 taken orally,20 mg per time, twice a day and continuously for 2 courses of treatment.In control group,patients have been treated only by chemotherapy.After treatment were completed,patients serum levels of VEGF, CEA,quality of life,toxicity and adverse effect were observed.Results After treatment were completed,compared with control group, serum levels of VEGF and CEA decreased obviously( P ＜ 0.05 )in experiment group and patients quality of life were improved obviously( P ＜ 0.05 ).The incidence of toxin and side effect in experiment group was obviously lower.Conclusion NSCLC patients who were in Ⅲ B and could not conduct operations accepting chemotherapy combined with ginsenoside Rg3 can inhibit tumor - related angiogenesis, increase the anti - tumor efficacy and improve the patients quality of life.%目的 观察人参皂苷Rg3对非小细胞肺癌患者血清VEGF水平及疗效的影响. 方法 选择ⅢB期不可手术切除的患者入组,实验组给予化疗同时口服Rg3 20mg,每日二次口服,用药2个疗程;对照组单纯给予化疗.用药结束后,观察患者血清VEGF、CEA水平变化情况,患者生活质量改善情况及毒副反应. 结果 用药2个疗程后,实验组患者血清VEGF水平明显下降为(315.7±15.2)pg/mL,CEA水平明显下降者占78%,生活质量KPS评分明显改善者为74.6%,毒副反应发生率明显减低,与对照组相比较均有显著性差异(P ＜0.05). 结论 对于ⅢB期不可手术切除非小细胞肺癌患者,给予化疗同时口服人参皂苷Rg3治疗,可抑制肿瘤新生血管的形成,增加抑瘤效果,改善患者生活质量.